- Parnell has launched Sevoflurane Inhalation Anesthetic for dogs.
- The product is indicated for the induction and maintenance of general anesthesia.
- Sevoflurane joins Parnell’s existing anesthesia portfolio, including propofol, dexmedetomidine, atipamezole and isoflurane.
- The company says the product is designed to provide a reliable and cost-effective anesthesia option for veterinary practices.
Parnell has expanded its veterinary anesthesia portfolio with the launch of Sevoflurane Inhalation Anesthetic, indicated for the induction and maintenance of general anesthesia in dogs.
The addition gives veterinary practices access to a broader range of anesthesia products from a single supplier, complementing the company’s existing offerings, including PropofolVet Multidose, dexmedetomidine hydrochloride injection, CONTRASED™ (atipamezole hydrochloride) and Isoflurane Inhalation Anesthetic.
According to Parnell, the nonflammable inhalant anesthetic is available in 250 mL bottles and is intended to provide clinics with a dependable and cost-conscious option for anesthesia protocols.
The launch also expands Parnell’s growing anesthesia business, which includes educational resources such as its Foundations of Anesthesia & Sedation Certificate Program, a RACE-approved continuing education course for veterinary professionals.
Information sourced from the company’s announcement.
